Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer
- Sponsor
- Rambam Health Care Campus
- Study ID
- NCT00192712
- Phase
- PHASE2/PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- irinotecan, gemcitabine — DRUG
Study Details
The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.
Key Dates
- First listed
- Sep 19, 2005
- Start date
- Nov 30, 2002
- Status verified
- Sep 2010
- Completion
- Sep 30, 2010
Study Design
- Enrollment
- 20 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
time to treatment failure
Find similar trials
Related Studies
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruiting · Mayo Clinic · Phoenix, Arizona
- Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer PatientsRecruiting · Vanderbilt University Medical Center · Nashville, Tennessee
- Pancreatic Adenocarcinoma Gene Environment Risk StudyRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic DiseaseRecruiting · Columbia University · New York, New York